88069-67-4 Usage
Uses
Used in Cardiology:
Pilsicainide is used as an antiarrhythmic agent for the treatment of cardiac arrhythmias, specifically targeting paroxysmal atrial fibrillation. It is administered orally and works by inhibiting sodium channels in the heart, thereby reducing the conduction and excitability of cardiac tissue. This action helps to prevent the rapid and irregular heartbeats associated with atrial fibrillation and assists in restoring a normal heart rhythm. Due to its fast onset of action, pilsicainide is particularly useful for the acute treatment of atrial fibrillation episodes. However, its use requires careful monitoring to manage potential proarrhythmic effects and ensure the safety and efficacy of treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 88069-67-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,8,0,6 and 9 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 88069-67:
(7*8)+(6*8)+(5*0)+(4*6)+(3*9)+(2*6)+(1*7)=174
174 % 10 = 4
So 88069-67-4 is a valid CAS Registry Number.
InChI:InChI=1/C17H24N2O/c1-13-6-3-7-14(2)16(13)18-15(20)12-17-8-4-10-19(17)11-5-9-17/h3,6-7H,4-5,8-12H2,1-2H3,(H,18,20)
88069-67-4Relevant articles and documents
New Anthiarrythmic Agents. N-Aryl-8-pyrrolizidinealkanamides
Miyano, Seiji,Sumoto, Kunihiro,Satoh, Fumio,Shima, Keiyu,Hayashimatsu, Mariko,et al.
, p. 714 - 717 (2007/10/02)
The synthesis and antiarrhytmic activity of N-aryl-8-pyrrolizidinealkanamides are described.The targed compounds were evaluated for their ability to protect against chloroform-induced fibrillation in mice.Many of them were found to have antifibrillatory activity comparable to that of lidocaine; several are more potent than lidocaine.N-(2,6-Dimethylphenyl)-8-pyrrolizidineacetamide (6n), which was found to be more potent and less toxic (LD50) than lidocaine, also showed a long duration of action in dogs with venticular arrhythmias after oral administration.